Home » News » Clinical Intelligence » Biohaven’s BHV-0223 granted Orphan Designation for ALS

Biohaven’s BHV-0223 granted Orphan Designation for ALS

Tuesday, December 13, 2016

The FDA has granted Biohaven Pharmaceutical‘s Orphan Drug designation request covering its drug candidate BHV-0223, an orally dissolving tablet being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS), also referred to as Lou Gehrig’s disease. This is the company’s third Orphan Drug designation request granted by the FDA.

ALS is a progressive neurodegenerative motor neuron disease that affects nerve cells in the brain and the spinal cord. The disease belongs to a group of disorders known as motor neuron diseases, which are characterized by the gradual degeneration and death of motor neurons. ALS affects up to 20,000 individuals in the U.S. and typically presents in patients with painless muscle weakness, trouble swallowing and muscle atrophy that ultimately progresses to paralysis and death. Since the FDA’s approval of riluzole in 1995, there have not been further clinical improvements or advances in ALS drug therapeutics over the last two decades. Several therapies are currently in clinical trials.

BHV-0223 is a sublingually absorbed and oral dissolving tablet (ODT) formulation of riluzole. BHV-0223’s novel formulation is designed to address some of the shortcomings associated with the solid oral dosage form of riluzole that ALS patients have difficulty swallowing. Because BHV-0223 is designed to be systemically absorbed through the oral mucosa, rather than through the gastrointestinal system, the company believes that it can eliminate the negative food effect associated with riluzole, bypass first-pass metabolism and deliver effective doses of the drug at lower concentrations, while also allowing sublingual absorption in patients who experience difficulty swallowing and eliminating the need for three hour fasting twice daily.

Robert Berman, M.D., CMO of Biohaven, said, “Patients with ALS develop a wide range of disabilities with the vast majority developing significant difficulty swallowing. Eventually, most muscles under voluntary control are affected, and individuals lose their strength and the ability to move their arms, legs, and body. As a sublingually administered and orally dissolving tablet form of riluzole, we believe that BHV-0233 may offer important advantages to ALS patients.”

Vlad Coric, M.D., CEO of Biohaven, added, “Receiving the orphan drug designation request approval for BHV-0223 in the treatment of ALS advances our global development strategy and one of our primary goals of providing therapies for patients suffering from neurologic disorders with high unmet need. If approved, this unique formulation will provide another therapeutic option to patients living with this devastating disease.”

“As shareholders in Biohaven we have been very impressed with Biohaven’s interaction with the FDA,” said Gregory Bailey, M.D., chairman of Portage “and the rapid progress they are making in the development of their products.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!